Skip to main content
MOBIMobia Medical, Inc.Sell6.0·$13.65+3.72%
Open full analysis

Mobia Medical, Inc. (MOBI) Stock Analysis

Range Bound setup

SellVALUE-TRAP 2/5Moderate Confidence

Healthcare · Medical Devices

Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $13.65 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.1): -1.5; Negative momentum.

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with... Read more

$13.65+27.5% A.UpsideScore 6.0/10#10 of 64 Medical Devices
QualityF-score5 / 9FCF yield
Stop $12.69Target $17.40(analyst − 13%)A.R:R 1.8:1
Analyst target$20.00+46.5%5 analysts
$17.40our TP
$13.65price
$20.00mean
$31

Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $13.65 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.1): -1.5; Negative momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 6.0/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-05

Recent Developments — Mobia Medical, Inc.

Generated 2026-07-05T09:50:25Z.

Thesis

Rewards
High-quality business
Strong growth profile
Analyst upside: 27%
Risks
Leverage penalty (D/E 4.1): -1.5
Negative momentum
Elevated risk factors

Key Metrics

P/E (TTM)
P/E (Fwd)-6.4
Mkt Cap$454M
EV/EBITDA-11.9
Profit Mgn-139.3%
ROE
Rev Growth113.3%
Beta
DividendNone
Rating analysts5

Quality Signals

Piotroski F5/9MoatNarrow

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
News Activity
5.0

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Value Rank
1.0
Growth Rank
9.7
Industry growth leader

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.5
Obv
1.0
Rsi
4.5
Macd
6.5
Ma Position
6.5
Volume distribution (falling OBV)
GatesMomentum 3.8<4.5A.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
57 · Neutral
20D MA 50D MA 200D MASupport $10.74Resistance $15.29

Price Targets

$13
$17
A.Upside+27.5%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 3.8 (below the engine's 4.5 threshold)

Earnings

M
M
M
M
0/4 beats

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MOBI stock a buy right now?

Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $13.65 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.1): -1.5; Negative momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $12.69. Score 6.0/10, moderate confidence.

What is the MOBI stock price target?

Take-profit target: $17.40 (+27.5% upside). Prior stop was $12.69. Stop-loss: $12.69.

What are the risks of investing in MOBI?

Leverage penalty (D/E 4.1): -1.5; Negative momentum; Elevated risk factors.

Is MOBI overvalued or undervalued?

Mobia Medical, Inc. trades at a P/E of N/A (forward -6.4). TrendMatrix value score: 6.3/10. Verdict: Sell.

0
What does Mobia Medical, Inc. do?Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for...

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.

Related stocks: DCTH (Delcath Systems, Inc.) · BWAY (Brainsway Ltd.) · TCMD (Tactile Systems Technology, Inc) · ATEC (Alphatec Holdings, Inc.) · CERS (Cerus Corporation)
Home Stocks MOBI

Latest news

Latest News

Benzinga3d agoFda Decision